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Abstract
Background: Adherence to therapies is a primary determinant of treatment success, yet the World Health
Organisation estimate that only 50% of patients who suffer from chronic diseases adhere to treatment
recommendations. In a previous project, we found that 30% of stroke patients reported sub-optimal medication
adherence, and this was associated with younger age, greater cognitive impairment, lower perceptions of
medication benefits and higher specific concerns about medication. We now wish to pilot a brief intervention
aimed at (a) helping patients establish a better medication-taking routine, and (b) eliciting and modifying any
erroneous beliefs regarding their medication and their stroke.
Methods/Design: Thirty patients will be allocated to a brief intervention (2 sessions) and 30 to treatment as usual.
The primary outcome will be adherence measured over 3 months using Medication Event Monitoring System
(MEMS) pill containers which electronically record openings. Secondary outcomes will include self reported
adherence and blood pressure.
Discussion: This study shall also assess uptake/attrition, feasibility, ease of understanding and acceptability of this
complex intervention.
Trial Registration: Current Controlled Trials ISRCTN38274953
Background
Adherence to therapies is a primary determinant of
treatment success. Poor adherence attenuates optimum
clinical benefits and therefore reduces the overall effec-
tiveness of health systems, yet it is estimated that in
developed countries, only 50% of patients who suffer
from chronic diseases adhere to treatment recommenda-
tions [1]. In the treatment of hypertension, it has been
estimated that only 30-50% of patients regularly take
their antihypertensive drugs as prescribed, and that non-
adherence may cause half of antihypertensive drug “fail-
ures” [2]. A recent illustrative example from the field of
cardiovascular disease is provided by the Duke Databank
for Cardiovascular Disease for the years 1995 to 2002,
which assessed the annual prevalence and consistency of
self-reported use of aspirin, b-blockers, lipid-lowering
agents, and combinations of the 3 drugs in patients with
coronary artery disease. Rates of consistent self-reported
medication use were sobering: aspirin (71%), b-blocker
(46%), lipid-lowering agent (44%), aspirin and b-blocker
(36%), and 21% for all 3 medications. Overall, consistent
use was associated with lower adjusted mortality,
although in this study the authors were unable to differ-
entiate patient non-adherence from physician non-pre-
scription [3]. In a further study of drug adherence and
mortality in 31,455 survivors of myocardial infarction
who were taking statins and b-blockers, patients were
divided into 3 adherence categories: high, intermediate
and low. After 1 year, compared with the high-adher-
ence group, low adherers to statin therapy had a 25%
increased risk of mortality [4]. Thus, polypharmacy is
the norm, self-reported adherence is often suboptimal,
and this is associated with elevated mortality risk [5].
The most recent Cochrane review of interventions to
improve medication adherence concluded that, “Current
methods of improving adherence for chronic health pro-
blems are mostly complex and not very effective, so that
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the full benefits of treatment cannot be realized. High
priority should be given to fundamental and applied
research concerning innovations to assist patients to fol-
low medication prescriptions for long-term medical dis-
orders” [6]. Our aim is to improve medication
adherence in the secondary prevention of stroke. Stroke
is the third most common cause of death in the UK,
and is the most common cause of severe physical dis-
ability amongst adults. The National Audit Office
recently estimated that the annual cost of caring for
people with stroke is £7 billion per year in the UK alone
[7]. The risk of a recurrent stroke is 30-43% within 5
years, and it is estimated that, currently, 11,626 strokes
occur annually in the Scottish population [8]. Large ran-
domised controlled trials and meta-analyses have identi-
fied several drugs which significantly reduce the risk of
future vascular events after stroke. The Scottish Inter-
collegiate Guidelines Network (SIGN) guidelines for sec-
ondary prevention after stroke now recommend
antiplatelet therapy and reduction of both blood pres-
sure and cholesterol level [9]. The estimated efficacy of
these drugs in helping prevent a further stroke in Scot-
land is outlined in Table 1.
A major risk factor for recurring vascular events or
death is therefore non-adherence to medication, but
only limited data are available on patient adherence to
medication intended to prevent recurrent stroke. How-
ever, there is no reason to believe that stroke patients
should demonstrate better adherence than in other
chronic conditions. In fact, the reverse is more plausible,
given that stroke often causes memory impairment,
which is known to cause adherence problems. In a
study of over 3,000 patients in Germany, Hamann et al.
[10] reported that 84% were still taking aspirin at one-
year post stroke, 77% oral anticoagulants, but only 61%
who were prescribed clopidogrel at discharge were still
taking it one year later. Sappok et al. [11] also reported
from a follow-up study one year after stroke and found
that only 70% of patients were still taking cholesterol-
reducing treatment. Data from the Netherlands revealed
that by 1 year after ischaemic stroke, 22% of patients
who had been taking oral anticoagulation had stopped,
half of whom did so “for non-medical reasons” such as
perceived adverse effects, patient request etc. [12]. Thus,
the available data on stroke patients suggest that adher-
ence is often sub-optimal, and that many patients are
consequently at a significantly increased risk of a further
stroke and/or cardiovascular event.
Fractionating Adherence
Adherence is the end result of a complex set of percep-
tions, attitudes, cognitive abilities, intentions and beha-
viours. It has proved useful to distinguish between
deliberate non-adherence (intentional) and non-deliber-
ate non-adherence (non-intentional) [1]. The aim of this
pilot project is to improve intentional adherence by
addressing beliefs that act as a barrier to adherence and
to reduce non-intentional non-adherence by developing
plans to help reduce forgetting.
Intentional non-adherence
Our theoretical framework is based around Leventhal’s
self-regulation theory [13]. This theory posits that
patients have a common-sense model of their illness in
terms of beliefs regarding how long a condition will last,
whether it is acute or chronic, what sort of treatments
will help, etc. Superimposed upon this framework of ill-
ness beliefs are beliefs about treatment, particularly the
perceived necessity of medication versus concerns about
possible harmful effects of medication [14]. Our recently
completed study [15] on determinants of adherence in
stroke patients supported self-regulation theory: it iden-
tified that stroke patients’ concerns about their medica-
tion (e.g. dependence, toxicity, too many tablets) were
key determinants of poor adherence. We therefore aim
to elicit and attempt to modify erroneous beliefs about
medication and stroke in this pilot randomised trial of a
brief intervention.
Non-intentional non-adherence
Many patients forget to take their medication as direc-
ted. Our previous study on adherence in stroke patients
established that cognitive impairment (as measured by
the Mini Mental State Examination (MMSE)) was signif-
icantly associated with poor adherence [15]. An impress-
ive body of evidence has accumulated showing that brief
Table 1 Estimated impact of pharmaceutical interventions to prevent recurrent strokes in Scotland
Intervention Number of Strokes avoided % of all strokes in Scotland
Aspirin 926 (8%)
Statins to reduce cholesterol 854 (7%)
Drugs to reduce blood pressure 751 (6%)
Dipyridamole added to aspirin 432 (4%)
Anticoagulants 376 (3%)
Taken from Health in Scotland 2007, Annual Report of the Chief Medical Officer, based on Table 18.4 in Warlow et al. [8]. The numbers in the table are derived
from applying estimates from randomised trials and meta-analyses of the reduction in stroke risk achieved by adding each intervention sequentially to the
previous one(s), assuming that these interventions are fully adhered to by all eligible patients with ischaemic stroke or transient ischaemic attack (TIA) in
Scotland. Untreated recurrent stroke risks are derived from UK population-based stroke registry data.
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and easy-to-complete implementation intentions inter-
ventions are effective at reducing forgetting and in
improving medication adherence [16]. These involve
patients writing down exactly when and where they
will take their medication, using the format of an if-then
plan ("If it is time X in place Y and I am doing Z, then I
will take my pill dose”). The evidence clearly indicates
that if-then planning makes people highly sensitive to
the cues that they have written down, and means that
they can act swiftly and effortlessly as soon as these
cues are encountered, thus environmentally cued habits
are established. Implementation intentions remove the
burden of having to think about and remember when to
act by using environmental cues to trigger the desired
behaviour. The load on prospective memory is reduced
as habitual responses are established (e.g. first cup of tea
at breakfast in the kitchen cues taking morning medica-
tion). In a recent example, Brown et al. [17] showed
that a simple if-then plan in epilepsy patients resulted in
intervention participants showing improved adherence
relative to controls on all three outcomes: doses taken
in total (93.4% vs. 79.1%), days that correct dose was
taken (88.7% vs. 65.3%), and doses taken on schedule
(78.8% vs. 55.3%), all p < .01. Importantly, participants
with the greatest degree of cognitive impairment bene-
fited most from the intervention [17].
Framework
We have developed our intervention using the new
Medical Research Council (MRC) Guidance on develop-
ing and evaluating complex interventions [18]. We have
completed the development work of the MRC frame-
work and have identified the evidence base, utilised an
appropriate theoretical model of adherence (self-regula-
tion), and identified process variables that relate to both
intentional and non-intentional adherence. We now
wish to embark on feasibility/piloting where we will test
a brief intervention, in terms of recruitment, retention,
acceptability and efficacy, and use the results of the
pilot to inform the sample sizes required for a larger,
more definitive trial. The intervention has two compo-
nents, tackling both intentional and non-intentional
non-adherence, and each component has a strong, sup-
portive evidence base.
We recently found that 30% of stroke patients
reported sub-optimal medication adherence at interview.
Approximately one third of the variance in self-reported
poor adherence was predicted by the following four
variables: (1) younger age, (2) greater cognitive impair-
ment, (3) lower perceptions of medication benefits, and
particularly, (4) greater specific concerns about medica-
tions (toxicity, side effects etc.) [15]. Our qualitative
interview findings confirmed the questionnaire results
by showing that (a) medication concerns were key
determinants of medication taking behaviour and also
(b) the establishment of a habitual routine for medica-
tion taking was seen as vital. The findings from that
study justify the evaluation of a pilot intervention trial
aimed at targeting both intentional and non-intentional
components, with the goal of improving medication
adherence.
Aims
To pilot the feasibility of a brief intervention in stroke
patients exhibiting sub-optimal adherence with the aim
of:
(a) establishing a better medication taking routine
using an implementation intentions intervention
(b) eliciting and modifying any emergent erroneous
beliefs regarding the patient’s medication and their
stroke.
We will test whether medication routines and beliefs
are changeable, and if the results are promising, this will
pave the way for a larger randomised controlled trial
(RCT) to determine whether adherence is improved,
physiological risk is changed (e.g. via reduction in blood
pressure), and rate of recurrent vascular events is
reduced.
Research questions
(a) Is the brief intervention feasible, understandable and
acceptable (e.g. regarding uptake/attrition)?
(b) Does the intervention improve adherence?
(c) Is improvement in adherence mediated by (i)
changes in illness and medication beliefs and/or (ii)
reduced forgetting?
(d) What effect size is observed to inform the power
calculation for a larger, more definitive study?
Methods/Design
Recruitment
In order to maximise recruitment and the representa-
tiveness of the sample, we shall attempt to recruit and
obtain consent from consecutive patients who are dis-
charged from the Edinburgh Western General Hospital
stroke units and clinics and who are prescribed second-
ary antihypertensive medication. Our previous experi-
ence suggests that this approach will significantly
improve trial recruitment. Currently approximately 300
in-patients and 400 out-patients are discharged per year,
with over 60% prescribed antihypertensive medication.
We will screen 400 first-time stroke (ischaemic and hae-
morrhagic) or Transient Ischaemic Attack (TIA)
patients, and expect a 75% response rate (300). We plan
to include both stroke and TIA patients since both
groups of patients are treated in a similar way with sec-
ondary prevention drugs and are likely to have similar
issues with respect to non-adherence [9]. We have
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decided to focus on the early months following stroke in
order to maximise the likelihood of preventing a further
stroke. Poor adherence will have a much greater effect
on stroke risk in the first few months because the risk
of stroke (and thus the absolute risk reductions asso-
ciated with drug treatment) is highest at this stage [19].
Furthermore, following Petrie et al. [20], we believe that
the efficacy of the intervention will be enhanced by eli-
citing and correcting dysfunctional stroke and medica-
tion beliefs soon after preventative drugs are started.
However, we have to strike a careful balance between
early intervention, and also allowing enough time for
participants to demonstrate variance in adherence, so
that we can specifically target those showing sub-opti-
mal adherence, thus our decision to assess adherence at
3 months post stroke or TIA. Consenting participants
will therefore be contacted by post 3 months after their
event and asked to complete the Medication Adherence
Self Report Scale (MARS) [21] and return it in a
stamped addressed envelope. In this mailing, we will
also ask participants to complete the Brief Illness Per-
ceptions Questionnaire [22] and the Beliefs about Medi-
cation Questionnaire [23]. This will allow us to
economically test the robustness and replicability of the
association we previously observed between specific
medication concerns and self-reported adherence in a
new large sample of TIA/stroke patients. We will then
invite all those reporting sub-optimal adherence on the
MARS (score of 24 or less) to participate. Based on our
earlier study we conservatively estimate that approxi-
mately 30% will report some degree of poor adherence,
and of those, up to 30% may then decline to participate.
We therefore estimate that if we invite 90 patients, 60
will agree to participate. They will then be randomly
allocated to brief intervention or treatment as usual
(TAU). We are allowing for a further 10% attrition rate
during the trial, however, one of the main purposes of
this pilot is to obtain data on uptake, acceptability and
attrition.
Inclusion criteria
We aim to be as inclusive as possible and recruit all
patients who had their first ischaemic or haemorrhagic
stroke or TIA 3 months earlier and were discharged
from the ward or clinic on any secondary preventative
medication and are living at home.
Exclusion criteria
We will only exclude people who are not on anti-
hypertensive medication 3 months after their stroke/
TIA, or whose degree of aphasia (Frenchay screen <13/
20) or MMSE <23 makes completion of the study mea-
sures not feasible. Those who report already using
Dosette boxes to improve their adherence, or are not
responsible for taking their own medication, will also
be excluded.
Design
A pilot RCT with patients allocated to intervention ver-
sus treatment as usual (TAU). Web-based randomisa-
tion at the patient level into intervention or TAU will
be provided by the Edinburgh Clinical Trials Unit, using
minimisation with a random element to ensure that the
two trial arms are not significantly different on three
key variables: age, number of pills taken per day and
baseline MARS adherence. A CONSORT flowchart of
the trial design is shown in Figure 1.
Setting
A single-centre trial at a large teaching hospital in
Scotland.
Ethical Approval
Ethical approval has been granted by Lothian NHS
Board, South East Scotland Research Ethics Committee
(REC ref. no. 09/S1102/36).
Measuring Adherence
There is no agreed “gold standard” when measuring
adherence [21]. Our previous study clearly established
that assay of urinary aspirin levels in stroke patients
lacked sensitivity and was unhelpful [15]. Garber et al.
[24] showed that appropriately framed self-report ques-
tionnaires show good concordance with electronic cap
monitors and blood and urine measurement. The
MARS attempts to reduce social desirability effects by
framing questions so to make non-adherent responses
socially acceptable. The MARS has high internal and
test-retest reliability, and has been shown to predict
clinical outcome (blood pressure within range [21]). We
used the MARS as our primary outcome measure in our
previous study, establishing that stroke patients found it
easy to use and understand, and we demonstrated that
MARS scores were not correlated with a social desirabil-
ity measure but were prone to ceiling effects [15]. We
will therefore use the MARS as a viable and economic
screen for patients demonstrating sub-optimal adher-
ence, but will then use MEMS (Medication Event Moni-
toring System, MEMS® Aardex Ltd, Switzerland) pill
containers which electronically record openings as our
primary outcome measure in the evaluation of this pilot
RCT.
Intervention
Two brief sessions, two weeks apart with a trained
Research Fellow, lasting approximately 30-45 minutes
each. Participants will be given the choice of having
home visits or coming into a local hospital-based Clini-
cal Research Facility.
Session 1 will focus on helping each patient draw up a
specific plan, so as to establish a better medication-taking
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routine using an implementation intentions approach.
Patients will be helped to complete an individualised
worksheet plan for each scheduled daily dose of antihy-
pertensive medication, following Brown et al. [17]. The
participant and Research Fellow will both keep a copy of
the plan. Baseline blood pressure readings will also be
taken during Session 1.
Session 2. The effectiveness of the implementation
intentions plan and any barriers/difficulties in following
the plan will be reviewed in session 2, with individually-
tailored coping strategies/plans developed collabora-
tively, following the methods outlined by Sniehotta et al.
[25]. This session will also focus on eliciting and, if
appropriate, challenging patients’ beliefs regarding their
medication, e.g. beliefs regarding toxicity, dependence,
fears regarding medications interacting harmfully etc.,
using the participants’ responses on the BIPQ and the
BMQ as a basis. The aim here will be to correct any
misperceptions and provide evidence so that partici-
pants’ medication necessity beliefs come to outweigh
their medication concerns beliefs. Previous work has
demonstrated that better adherence results when medi-
cation necessity beliefs outweigh concerns [14]. Modifi-
cation of erroneous beliefs about stroke will be based on
Figure 1 CONSORT flowchart of trial design.
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the model of Petrie et al. [20] who elicited and modified
patients’ dysfunctional beliefs regarding their recent
myocardial infarction. This resulted in faster return to
work and lower angina symptoms at 3 months. If the
Research Fellow is unable to answer any specific ques-
tions regarding the patient’s stroke or medication, then
immediately following the interview, the RA will email
the query to one of the stroke consultant experts on the
research team, and the RA will then telephone the
patient with the information within 7 days of the inter-
view. At the end of session 2, the Research Fellow will
fill each participant’s MEMS medication bottle with the
following month’s supply of antihypertensive medica-
tion. (We propose using the patients’ existing supply of
antihypertensive medication. A check will be taken at
session 1, and if supplies are running low, participants
will be asked to obtain their repeat prescription in
advance of session 2). For each of the next three months
(Sessions 3-5), the Research Fellow will repeat this pro-
cess, and also take an electronic reading from the
MEMS cap, downloading the data on to a laptop PC for
later analysis. At the first of these follow-up visits (Ses-
sion 3), participants will again complete the Brief Illness
Perceptions Questionnaire (BIPQ) [22] and the Beliefs
about Medications Questionnaire (BMQ) in order to
test whether the intervention has resulted in changes to
stroke and/or medication beliefs [23]. At the final visit,
at 3-month follow-up (Session 5), the outcome measures
will be administered.
Control condition
Participants in the control group will receive the same
number of Research Fellow visits and will complete the
same questionnaires at the same timepoints as the inter-
vention group. MEMS readings and BP recordings will
also be taken, as detailed in the intervention arm. Dur-
ing the first 2 sessions, the Research Fellow will also
engage control group participants in non-medication
related conversation, e.g. how they are feeling, how they
are spending their time etc. in an attempt to provide
some control for non-specific effects of attention/social
contact.
In both conditions, all interviews will be timed and
digitally audio-recorded and transcribed for supervision
feedback and check on treatment fidelity.
Primary outcomes
Medication adherence will be recorded using MEMS
(Medication Event Monitoring System, MEMS® Aardex
Ltd, Switzerland) pill containers which electronically
record openings. Following Brown et al. [17], and in line
with previous studies using this method, we shall use
the following main outcomes, counting each opening as
a presumptive dose: (a) percentage of doses taken
(versus doses prescribed), (b) percentage of days on
which the correct number of doses was taken, and (c)
percentage of doses taken on schedule. Again, following
Brown et al. [17], we designate doses as having been
taken on schedule if the MEMS bottle was opened
within a 3-hour (plus or minus) time window for each
dose. The electronic monitoring caps can be connected
to a personal computer that reads the data from the pill
caps’ microprocessors and generates a printout of every
pill bottle opening over an extended time period (in this
case, the preceding month). Because patients will usually
be on a variety of medications, we will target antihyper-
tensive medication for MEMS measurement, particularly
as there is clear evidence regarding poorly treated blood
pressure significantly increasing the risk of future vascu-
lar events, and as stated in the introduction, it is esti-
mated that only 30-50% of patients regularly take their
antihypertensive drugs as prescribed [2]. If patients are
taking more than one antihypertensive, we shall target
the drug that is taken most frequently. MEMS have
been successfully used in a variety of medication adher-
ence interventions e.g. Brown et al. [17]. However, as
with most methods in this area, MEMS measurement is
not immune from the Hawthorne effect, i.e. medication-
taking behaviour is often improved in the short-term as
a direct consequence of it being measured [26]. We
shall therefore use MEMS containers to record medica-
tion taking in both intervention and control arms for 3
months. We predict in the control arm that adherence
will gradually drop off over the 3 months (as the
Hawthorne effect fades), whereas there will be an
increase or no change over the 3 months in the inter-
vention arm. A recent three-month RCT aimed at
improving adherence to medication in HIV-affected
individuals also used this MEMS evaluation of outcome,
and in the intention to treat analysis showed no change
in the TAU arm, but a significant improvement in the
psychological intervention arm, with a controlled effect
size of 1.0 [27]. We acknowledge the limitation in this
pilot that the Research Fellow will not be blind to treat-
ment arm; however, as our primary outcome is MEMS
automated recording of days per month that the correct
dose of hypertensive was taken, the potential for bias is
significantly reduced.
Secondary outcomes will include (a) MARS self-
reported adherence of all secondary preventative medi-
cation, (b) systolic and diastolic blood pressure.
Analysis
MEMS data will be analysed using an intention to treat
protocol in a repeated-measures mixed-design (2 groups
* 3 time points). One of the primary aims of this pilot
study is to determine the effect size achieved by this
pilot to inform the sample size calculation for a larger,
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more definitive multi-centre study. (We acknowledge
that the effect size observed may differ from what one
would see in a large trial, however, the effect size sought
in the large trial should be within the 95% CI of the
estimate derived from this pilot. The pilot will thus give
a useful measure of the variability of the primary out-
come measures). Using G-Power [28] for this pilot, we
calculate that with 2 arms of 30 participants, focusing
on the treatment group by time interaction term, we
should be able to detect an effect size of 0.2, with a
power of 0.80 and alpha set at 0.05 (i.e. a 0.2 of a stan-
dard deviation improvement in the brief intervention
arm in number of days per month that the correct anti-
hypertensive medication is taken, relative to the
TAU arm).
Control variables
At Session 1, following Trewby et al. [29] and our pre-
vious study, all participants will be asked to complete a
baseline measure of their perception of the benefit (0-
100%) provided by their current stroke prevention medi-
cation using a simplified graphical presentation card.
Participants will also complete the Mini-Mental State
Examination (MMSE), as we previously demonstrated
that younger age, lower MMSE and low perceived bene-
fit of medication were all related to poor adherence
[15]. Finally, we will determine whether these, and other
baseline characteristics (e.g. prior use of reminder
packaging and partner involvement in reminding to take
medication), are related to treatment outcome.
Evaluation
The effects of the intervention will be evaluated in all
participants via measurement of the primary and sec-
ondary outcome variables listed above. The Research
Fellow will also take baseline and 3-month follow-up
blood pressure measurements using an OMRON M10-
IT BP monitor following a standardised protocol (mean
of 3 recordings). The blood pressure results will be fed
back to the participants and their GPs in both interven-
tion and TAU arms, together with simple information
regarding ideal values. (NB we do not expect significant
change in these physiological variables in this pilot, but
these may change - albeit over a longer time period - in
a larger trial and we wish to assess feasibility and patient
acceptability). On completion, patients in the interven-
tion arm only will also take part in a brief semi-struc-
tured interview to assess their views regarding the
intervention. They will also be asked to complete Likert-
type scales assessing (a) ease of understanding, (b)
acceptability and (c) perceived benefit for each of the
intervention components, namely, 1) medication routine
planning worksheet, 2) discussion/information regarding
medication, 3) discussion/information regarding stroke,
and 4) blood pressure measurement. Additional file 1:
Table S1 details all patient contacts and assessments at
each time point.
Process evaluation
We will test if any change in adherence is mediated by
changes in medication beliefs (Beliefs about Medications
Questionnaire - BMQ) and/or illness beliefs (Brief Ill-
ness Perceptions Questionnaire).
Timetable
This is a 31-month project. The Research Fellow will
spend months 1-3 learning techniques for eliciting and
modifying patients’ dysfunctional beliefs regarding their
stroke and their medication. Patients will be invited to
participate from month 3 onwards. It is anticipated that
the running of the trial will take 24 months (months 4-
27). Postal recruitment will be used to collect baseline
data on the MARS, BMQ and BIPQ self-report mea-
sures, and to identify participants who are suitable for
the intervention. Each participant recruited into the
intervention will participate for roughly four months,
thus we envisage 6*4 month blocks, with approximately
10 patients being run concurrently in any one of these
blocks. They will each require 5 face-to-face contacts
(choice of home visit or meeting in the local Clinical
Research Facility) over the participation period. Session
1 is when the remaining baseline measures will be com-
pleted and the implementation worksheet plan drawn
up. Session 2 is two weeks later when the plan is
reviewed and elicitation and modification of illness and
medication beliefs will be conducted, and the MEMS
containers filled for the following month. Sessions 3 and
4 are brief monthly meetings to take a MEMS cap read-
ing and refill the MEMS bottle. BMQ and BIPQ scores
will also be collected at Session 3. The final outcome
measures will be taken at Session 5. Months 28-31 will
be spent analysing the data and in preparing the final
report and papers for conference presentation and
publication.
Discussion
Improving adherence to appropriate prescriptions of
existing efficacious treatments may well represent the
best investment for improving self-management of long-
term medical conditions [1]. This work has the potential
to improve adherence, treatment efficacy and reduce
health service waste. A health economic evaluation
would be central to any subsequent large-scale trial.
This pilot trial is a logical development from our recent
study of determinants of medication adherence in stroke
patients [15], and is novel in that it is targeting both
intentional and non-intentional non-adherence via belief
modification and implementation intentions respectively.
The intervention is based on self-regulation theory and
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is brief, practicable and capable of being delivered by
trained non-specialist health workers in an NHS setting.
In a recent critical evaluation of adherence interventions
[21], 6 consistent weaknesses in the field were identified:
1) narrow focus for intervention, in particular a failure
to consider both intentional and non intentional non-
adherence, 2) “one size fits all” approach i.e. not patient-
centred, 3) failure to specify the content of the interven-
tion, 4) “black box” evaluation, 5) lack of theoretical fra-
mework and 6) little or no process evaluation. Our
proposed study addresses each of these weaknesses in
that we are tackling intentional and non-intentional
non-adherence, are using a patient-centred approach by
eliciting individualised concerns, are describing the nat-
ure and content of the intervention, thus allowing for
replication, are using Leventhal’s self-regulatory model
as our theoretical framework and are testing process by
assessing whether change in adherence is attributable to
changes in illness and/or medication beliefs and/or
reduced forgetting. This work has the potential to signif-
icantly improve the efficacy of a broad range of treat-
ments in the NHS. If the results of the pilot are
promising, a larger more definitive study in stroke
patients would be planned and similar evaluations in
other chronic conditions should also be considered.
Additional file 1: Table S1: Details and schedule of IAMSS
assessment procedures. The table shows all patient contacts and
details of the assessments taken at each time point.
Click here for file
[ http://www.biomedcentral.com/content/supplementary/1471-2377-10-
15-S1.DOC ]
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